<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636099</url>
  </required_header>
  <id_info>
    <org_study_id>QYFYKYLL791311920</org_study_id>
    <nct_id>NCT04636099</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Surgery Study Group 2001</brief_title>
  <acronym>GISSG2001</acronym>
  <official_title>Preoperative CTA to Evaluate the Influence of Gastric Artery Type on the Clinical Outcome of Gastric Cancer Patients With BMI≥25.0 kg/m2：A Multicenter Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Province Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weifang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weifang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Jining No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weihai Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weihai Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongying People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rizhao People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Jimo District, Qingdao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaocheng People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is one of the most common malignace worldwide, which caused a dramatically&#xD;
      death rate, especially in east Asian, such as Japan , South Korea and China. Although the&#xD;
      treatment of gastric cancer has a large improvement, such as radiotherapy, chemotherapy and&#xD;
      immunotherapy, surgery is yet the mainstream method for the curable malignace without distant&#xD;
      metastasis. As the innovation of treatment in gastric caner, laprascopic has gain its&#xD;
      popularity owing to its equivalent oncologic outcomes, earlier oral feeding, shorten&#xD;
      postopertative of hospital length,compared with open surgery. Depite it has several&#xD;
      advantages, the defect of laparascopic surgery is still obvious, such as 2D surgical field,&#xD;
      lack of inverse haptic feedback, Inflexible equipment.&#xD;
&#xD;
      D2 Lymph node dissection associated with laparascopic gastronomy is still regard as standard&#xD;
      surgical procedure for the gastric cancer patient whose tumor stage was evaluated in advance&#xD;
      stage. As we known that the distribution of lymph nod is accompanied with blood vessels, even&#xD;
      for well-trained surgeon, the procedure lymph node dissection is a challenging and tough&#xD;
      work. Computed Tomography Angiography(3D-CTA), as a emerging technology, is gradually receive&#xD;
      the surgeon's attention for its remedy characteristic to the defect of laparascopic surgery,&#xD;
      which can visually display the distribution and type of perigastric artery, resulting in&#xD;
      decresing the difficulty and risk of surgery.&#xD;
&#xD;
      The aim of the study is to investigate the clinincal outcomes for the patient with BMI ≥25&#xD;
      kg/㎡who underwent laparascopic or robotic gastronomy using CTA to evaluate the type of&#xD;
      perigastric artery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>during the surgery</time_frame>
    <description>haemorrhagia amount during the operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lymph node dissection guided by vessel</measure>
    <time_frame>during the surgery</time_frame>
    <description>the harvest of lymph node during the gastronomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total incidence of postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>the postoperative complications was defined as the complications related to the surgery or systematic,such as pneumonia,urinary tract infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery course</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation, flatus, liquid diet and so on</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>the 30-day mortality was defined as the death occurs related to the surgery or other occasions within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization costs length of hospitalization days</measure>
    <time_frame>during the hospitalization</time_frame>
    <description>the total cost of hospitalization related to any therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 years OS</measure>
    <time_frame>3 years</time_frame>
    <description>3 years overall survival after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 years DFS</measure>
    <time_frame>3 years</time_frame>
    <description>3 years disease free survival after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">382</enrollment>
  <condition>Gastrostomy</condition>
  <condition>Computed Tomography Angiography</condition>
  <condition>Clinical Outcome</condition>
  <arm_group>
    <arm_group_label>CTA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-CTA Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The CTA group was routinely peformed upper abdomen enhenced without CT Angiography before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CT angiography（CTA）</intervention_name>
    <description>The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery</description>
    <arm_group_label>CTA Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathological diagnosis of gastric adenocarcinoma by gastroscopy&#xD;
&#xD;
          2. Age 18~75 years old&#xD;
&#xD;
          3. BMI≥25.0kg/m2&#xD;
&#xD;
          4. Preoperative imaging staging is T1~T4a, N0~3, M0&#xD;
&#xD;
          5. The surgical approach is laparoscopic surgery and robotic surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients whose tumors stage are found to be T4b or M1 during the operation, tumors are&#xD;
             unresectable and accompanied with malignant tumors in other parts;&#xD;
&#xD;
          2. suffering from other malignant tumors, tumors of low malignant potential (giant cell&#xD;
             tumor of bone, pseudomyxadenoma of appendix, invasive fibroma) in the past;&#xD;
&#xD;
          3. Patients who have serious other system diseases and cannot tolerate surgery;&#xD;
&#xD;
          4. Patients with non-adenocarcinoma type malignant tumors in pathology after surgery;&#xD;
&#xD;
          5. Patients with residual gastric cancer;&#xD;
&#xD;
          6. Those who are allergic to iodine contrast agents;&#xD;
&#xD;
          7. Those who have received neoadjuvant therapy before surgery;&#xD;
&#xD;
          8. Pregnant patients;&#xD;
&#xD;
          9. Patients who are participating in other clinical studies trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhou Yanbing, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Affiliated Hospital of Qingdao University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhou Yanbing, MD</last_name>
    <phone>86532-82911324</phone>
    <email>zhouyanbing999@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meng Cheng, MD</last_name>
    <phone>86532-82911324</phone>
    <email>pandamch@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou Yanbing</last_name>
      <phone>86532-82911324</phone>
      <email>zhouyanbing999@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

